Science Corporation PRIMA retinal BCI: expanding from AMD to Stargardt disease and retinitis pigmentosa
Summary
Science Corporation published clinical data extending the PRIMA photovoltaic subretinal implant program beyond geographic atrophy (advanced AMD) to two additional inherited retinal conditions: Stargardt disease and retinitis pigmentosa. Both conditions cause progressive vision loss through photoreceptor degeneration and, like AMD, present with intact downstream retinal circuitry that PRIMA can activate. Early trial data suggests comparable restoration of functional visual acuity in Stargardt and RP patients to the 80% success rate published in the PRIMAvera AMD study in NEJM.
Why it matters
Stargardt disease and retinitis pigmentosa combined affect approximately 2.5 million people globally — comparable in total numbers to geographic atrophy AMD. Both are leading causes of blindness in children and young adults rather than the elderly population affected by AMD. PRIMA's expansion to these indications transforms Science Corporation from an elderly AMD company to a broad inherited and degenerative retinal blindness platform, dramatically expanding both the clinical impact and the commercial addressable market.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial